SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is generating significant investor interest following a major U.S. commercialization partnership with Tolmar and positive clinical trial progress across multiple oncology indications. The community is actively discussing the company's robust pipeline, significant de-risking milestones, and the disconnect between the stock's current price and its strong long-term growth potential.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is gaining market attention as investors speculate on the potential of its selective ITK inhibitor, soquelitinib, with community members actively discussing upcoming data readouts and potential partnership or acquisition opportunities. The stock is seeing heightened volatility as market participants debate the company's long-term pipeline value against ongoing short interest and recent institutional ownership shifts.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO Inc. is currently seeing significant volatility and intense discussion as investors navigate the final stages of the company's transformative acquisition of TopBuild. While some community members remain deeply bullish on Brad Jacobs' track record and the long-term potential for market dominance, others are expressing frustration over the stock's recent downward pressure, attributed by many to institutional short-selling, arbitrage activity, and market-wide macro concerns.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is facing intense scrutiny as investors grapple with leadership departures, high-profile insider selling, and concerns over the company's timeline for converting AI data center demand into sustainable revenue. While bulls highlight Navitas' participation in the NVIDIA MGX ecosystem and its next-generation power efficiency technology as drivers for long-term growth, the stock is experiencing significant volatility driven by concerns over potential dilution and sector-wide sentiment shifts.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending due to intense speculation surrounding an imminent buyout and the anticipation of the 80th clinical trial event. Investors are actively discussing the potential impact of institutional accumulation and the company's oncology pipeline, leading to high-conviction sentiment and debates over its valuation and regulatory path.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is trending following a post-earnings sell-off where investors reacted to moderate ARR growth despite strong revenue and a announced 4-for-1 stock split. The community remains divided, with some viewing the pullback as an attractive buying opportunity for a long-term cybersecurity leader, while others argue the stock remains fundamentally overvalued relative to its growth pace.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Nasdaq Inc. is trending as investors weigh structural changes following record-sized IPO filings from major entities like SpaceX and Anthropic, alongside increased market volatility and discussions around 24/5 clearing infrastructure. The community is actively debating the implications of AI on traditional financial data providers, the potential impact of algorithmic market structures, and the broader macro environment affecting market liquidity.

Select Sector SPDR Trust (The) - State Street Financial Select Sector SPDR ETF

Financial Select Sector SPDR Fund

The Financial Select Sector SPDR Fund (XLF) is seeing active interest as market participants debate whether recent bullish breakouts and rotational strength indicate a sustained sector lead or remain susceptible to recession-related headwinds. Traders are particularly focused on the upcoming earnings cluster, with ongoing discussions revolving around institutional accumulation, unusual options activity, and the sector's performance as a potential hedge against broader market volatility.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending as investors react to a newly secured $52.7 million contract modification with the U.S. government for the ACAM2000 vaccine, sparking discussions about potential biodefense momentum. While the community remains divided over short-term price action and insider activity, many are closely monitoring the stock's performance around key technical support levels as they anticipate future contract awards.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T shares are under pressure as investors weigh competitive concerns regarding SpaceX's expansion into consumer wireless services against the company's dividend yield and long-term infrastructure investment. The community is actively debating whether current valuation levels represent a generational buying opportunity for income-focused portfolios or if broader shifts in the telecommunications sector warrant caution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm PR Newswire LOS ANGELES, June 8, 2026 LOS ANGELES, June 8, 2026 /PRNewswire...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics, Inc. (Grace or the Company) (NASDAQ: GRCE) for violations of the securities laws.The investigation focuses on whether the Company issued false...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace...

GRCE Stock On Track For Worst Week In 5.5 Years —  What’s Driving The Selloff?

Equity

Earlier this week, the FDA refused to approve Grace Therapeutics’s experimental drug for the treatment of a severe form of acute brain injury.


GRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixable

Grace Therapeutics was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage. 


GRCE Stock In Spotlight Ahead Of FDA Verdict On Brain Bleed Drug This Week 

The FDA set a Prescription Drug User Fee Act target action date of April 23 to rule on GTx-104, a potential treatment for patients with aneurysmal subarachnoid hemorrhage.

Short Interest in Grace Therapeutics, Inc. (NASDAQ:GRCE) Grows By 300.8%

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Update

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling...

Grace Therapeutics (NASDAQ:GRCE) Announces Earnings Results

Grace Therapeutics (NASDAQ:GRCE - Get Free Report) posted its earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus...

Grace Therapeutics, Inc. engages in the development and commercialization of drug candidates for rare and orphan diseases. It focuses on utilizing proprietary technologies to improve the performance of currently marketed drugs. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Grace Therapeutics Inc.

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

GRCEGrace Therapeutics Inc.

Latest GRCE News